Bright Minds Biosciences Initiates Dosing in Phase IClinical Trial of BMB-101 for Dravet Syndrome

Press Release

— In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures —   Vancouver, BC – August 31, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders,…

BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF $4 MILLION UNIT OFFERING

Press Release

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.   Vancouver, BC – August 30, 2022 – Vancouver, British Columbia – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) of 2,858,000…